核苷(酸)类药物治疗慢性乙型肝炎患者影响HBeAg血清转换的免疫学因素研究进展  

Research Progress of Immunological factors influencing HBeAg seroconversion across chronic hepatitis B patients treated with nucleos (t)ide analogues

作　　者：曹辉[1] 张玮[1] 

机构地区：[1]上海中医药大学附属龙华医院肝病科,上海市200030

出　　处：《实用肝脏病杂志》2017年第3期372-376,共5页Journal of Practical Hepatology

基　　金：国家自然科学基金项目(编号:81373860);上海市中医中西医临床重点扶持项目(编号:ZY3-JSFC-1-1009)

摘　　要：宿主的免疫系统功能决定了乙型肝炎病毒(HBV)感染的最终转归。核苷(酸)类药物抗病毒治疗能快速降低病毒载量,恢复宿主的免疫功能,HBe Ag血清转换就是宿主免疫系统功能部分恢复的标志。本文介绍了近五年这个领域的相关基础及临床研究,探讨了天然免疫和获得性免疫与HBe Ag血清转换的相关性,为提高核苷(酸)类药物抗病毒治疗过程中的HBe Ag血清转换率提供依据。The function of host immune system determines the final outcomes of hepatitis B virus （HBV） infection. Antiviral treatment by nucleos（t）ide analogs can quickly reduce the viral loads and recovery host immune function. HBeAg seroconversion is a sign for at least a partial host immune system recovery. This paper reviews the relevant basic and clinical research in the nearly last 5 years to explore the correlation between innate immunity and acquired immunity with HBeAg seroconversion and tries to provide evidence for the improvement of HBeAg seroconversion rate in the nucleos（t）ide analogs treatment process.

关 键 词：慢性乙型肝炎 HBEAG血清转换 先天性免疫 获得性免疫 细胞因子 

分 类 号：R512.62[医药卫生—内科学]